MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	temozolomide + interferon α-2b Sensitive: B - Late Trials temozolomide + interferon α-2b Sensitive : B	temozolomide + interferon α-2b Sensitive: B - Late Trials temozolomide + interferon α-2b Sensitive : B
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	VAL-083 Sensitive: C3 – Early Trials VAL-083 Sensitive : C3	VAL-083 Sensitive: C3 – Early Trials VAL-083 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	UCPVax Sensitive: C3 – Early Trials UCPVax Sensitive : C3	UCPVax Sensitive: C3 – Early Trials UCPVax Sensitive : C3
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	BAL101553 Sensitive: C3 – Early Trials BAL101553 Sensitive : C3	BAL101553 Sensitive: C3 – Early Trials BAL101553 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	chlorpromazine Sensitive: C3 – Early Trials chlorpromazine Sensitive : C3	chlorpromazine Sensitive: C3 – Early Trials chlorpromazine Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	sunitinib + temozolomide Sensitive: C3 – Early Trials sunitinib + temozolomide Sensitive : C3	sunitinib + temozolomide Sensitive: C3 – Early Trials sunitinib + temozolomide Sensitive : C3

MGMT unmethylation

Associations